Last updated on April 17, 2014 at 11:13 EDT

Regentis Biomaterials Announces $10 Million Raised in Latest Round of Funding

May 14, 2012

OR AKIVA, Israel and PRINCETON, New Jersey, May 14, 2012 /PRNewswire/ –

Regentis Biomaterials Ltd., a privately held company focused on developing proprietary
hydrogels for tissue regeneration, announced that it has raised $10 million in its latest
round of funding from new investors Royal DSM through its venturing subsidiary and from
Crossroad Fund, as well as from existing investors Medica Venture Partners, SCPVitalife
and the Technion Investment Opportunities Fund.

The Series C round of financing will be used to establish Regentis’s European presence
and expand its ongoing clinical efforts of GelrinC. The biodegradable implant enhances
growth of articular cartilage in damaged knee joints. It is currently an investigational
device, and not available for sale in the U.S., Europe and Israel.

“We are thrilled with our new and existing investors’ commitment to make GelrinC
available to patients suffering from knee cartilage injuries,” said Regentis Biomaterials
CEO and President Dr. Alastair Clemow. “With this new investment, Regentis is poised to
expand its clinical efforts and further demonstrate how GelrinC can regenerate cartilage
so patients can return to an active lifestyle.”

The product allows knee cartilage to regenerate so that it is of high quality and fits
tightly with surrounding cartilage and underlying bone. It closely restores cartilage to
the condition it was in prior to injury. While there are cartilage repair techniques that
relieve pain and restore the knee’s functionality, the regenerated cartilage resulting
from these procedures is different in nature from the native cartilage and is often
followed by subsequent surgical procedure.

Regentis Biomaterials is currently conducting a multi-center pilot study in Europe and
Israel to evaluate the safety and performance of GelrinC. Prior pre-clinical studies have
successfully demonstrated its ability to regrow cartilage.

The company will be participating at the upcoming International Cartilage and Repair
Society (ICRS) with a hands-on GelrinC demonstration in Booth # 16. ICRS will be held May
12-15, 2012 in Montreal, Canada.

About Regentis Biomaterials
With offices in Or Akiva, Israel and Princeton, NJ, Regentis Biomaterials is a privately
held company focused on developing and commercializing proprietary hydrogels for tissue
regeneration. The company’s core technology is a biodegradable hydrogel called Gelrin(TM).
It is based on polyethylene glycol diacrylate and denatured fibrinogen originally
developed at the Technion – Israel Institute of Technology by Dr. Dror Seliktar. The
Gelrin hydrogel platform combines the stability and versatility of a synthetic material
with the bio-functionality of a natural substance for a range of clinical applications and
has undergone extensive preclinical and safety testing over the last few years. The
company’s flagship product, GelrinC(TM), designed for the treatment of articular cartilage
lesions, is currently in clinical trials. DSM – Bright Science. Brighter Living.(TM) Royal
DSM N.V. is a global science-based company active in health, nutrition and materials. By
connecting its unique competences in Life Sciences and Materials Sciences DSM is driving
economic prosperity, environmental progress and social advances to create sustainable
value for all stakeholders. DSM delivers innovative solutions that nourish, protect and
improve performance in global markets such as food and dietary supplements, personal care,
feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics,
life protection, alternative energy and bio-based materials. DSM’s 22,000 employees
deliver annual net sales of about EUR 9 billion. The company is listed on NYSE Euronext.
More information can be found at http://www.dsm.com. About Crossroad Fund Crossroad is a
foreign venture capital/private equity fund, in which the Italian insurance group Generali
is investing, focusing on the Israeli high-tech industry. Crossroad is represented by Bit
Enterprises Ltd.

About Medica Venture Partners Medica Venture Partners is a globally operating
healthcare and life sciences venture capital fund investing in Israel, Europe and the
United States. Medica provides equity financing, management assistance and expertise to
early-stage start-ups and seed-stage companies in all areas of healthcare and life science
technologies. For more information, visit http://www.medicavp.com.

About SCPVitalife SCPVitalife is a venture capital firm that focuses on life science
investments in the U.S. and Israel. The firm invests in companies with breakthrough
products that meet a current medical need and have strong intellectual property. For more
information, visit http://www.scpvitalife.com

Technion Investment Opportunities Fund The Technion Investment Opportunities Fund
(TIOF) is the investment fund of the Technion – Israel Institute of Technology. TIOF
offers a unique gateway to the Technion’s cutting edge scientific and technological
information and capabilities. The fund invests in coordination with other investors and
aims to preserve the equity stake in Technion related companies. For more information,
visit http://www.trdf.co.il.

        For more information, please contact
        Alastair Clemow, Ph.D.  President & CEO
        Tel: +972-4-6265502
        Fax: +972-4-6265504
        aclemow@regentis.co.il [Livnat@regentis.co.il ]

        For media inquiries, please contact:
        Josh Turner
        Tel: +972-54-949-6526

SOURCE Regentis Biomaterials Ltd.

Source: PR Newswire